Company Filing History:
Years Active: 2025
Title: Innovative Contributions of Nazanin Larijani Rohani
Introduction:
Nazanin Larijani Rohani is an accomplished inventor based in Montreal, Canada. She is recognized for her significant contributions to the field of biotechnology, specifically in the development of targeted cancer therapies.
Latest Patents:
Nazanin holds a notable patent titled "Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors." This groundbreaking invention focuses on anti-Her2 antibodies and their fragments, which are designed to bind to Her2-expressing cells. The binding mechanism operates with low affinity at physiological pH, typical of normal tissues, and exhibits high affinity at the slightly acidic pH characteristic of solid tumors. This invention not only effectively inhibits tumor spheroid growth comparably to the established antibody Herceptin at acidic pH, but also maintains this selectivity upon conjugation with cytotoxic drugs. The patent further encompasses various methodologies for treating, detecting, and capturing solid tumors based on pH-dependent mechanisms.
Career Highlights:
Nazanin Larijani Rohani collaborates with the National Research Council of Canada, where her pioneering research plays a crucial role in advancing cancer therapeutics. Her work focuses on innovative solutions aimed at enhancing the effectiveness of treatments for solid tumors.
Collaborations:
Nazanin's collaborative efforts include working alongside esteemed colleagues such as Traian Sulea and Jason Baardsnes. Together, they contribute to cutting-edge research that bridges the gap between scientific discovery and clinical application in oncology.
Conclusion:
Through her innovative patent and collaborative efforts, Nazanin Larijani Rohani exemplifies the spirit of innovation in the realm of biotechnology. Her research not only advances scientific understanding but also holds the promise of improved therapeutic strategies for patients battling solid tumors.